As the availability of large streams of data provides the ‘vehicle’ to drive change, never before has the saying ‘information is power’ been more true than in today’s evolving pharmaceutical industry.

Big data technologies make it easier to work with and link large datasets, detect patterns in real time, predict outcomes, undertake dynamic risk scoring and test hypotheses. Applying big-data strategies to better inform decision making could generate huge value across the health-care system by optimizing innovation, improving the efficiency of research and clinical trials and building new tools for physicians, consumers, insurers and regulators.

Following on from the phenomenal success of a portfolio of pharmaceutical events, SMI are proud to present the inaugural Big Data in Pharma Conference Monday 12th – Tuesday 13th May 2014, London. Focusing on how to efficiently utilize data to better identify potential drug candidates and develop more effective medicines, this is the year’s must attend event.

Join us and hear timely case studies and presentations from leading pharma, biotech and technology experts as they demonstrate how to create a winning big pharma strategy by turning raw data into informative, useful information that can work for you!

Key Topics include:-

• Building the ‘blueprint’ for a data-led pharmaceutical industry of the future
• Creating a successful big data organisational culture
• Forging winning strategic partnerships with patients, the public and industry to gain a competitive advantage
• Measuring the impact of big data on R&D
• Introducing data management and analysis to extract value

This 2 day networking event will invite in depth discussion of key drivers impacting big data in pharma providing a fantastic opportunity to hear from and talk to professionals currently operating in the market. Join the event of the year to:




• Hear cutting edging presentations and key cases studies from leading big data in pharma experts
• Network and learn from industry and academic opinion leaders
• Learn about the impact of big data on pharmaceutical R&D
• Discover how big data analysis can positively impact clinical trials 

Chief Information Officers, Chief Technology Officers, Heads of Data, Heads of Business Intelligence,
Heads VPs and Directors of:

• Analytics
• Research
• Enterprise/Data Architecture
• Data Experts
• Information Architecture
• Statistics
• Health Economics Outcomes Research
• Informatics
• IT Operations
• Innovation & Technology
• Laboratory Information Management Systems

3M Health Care; Abel and Imray; Amdipharm Mercury Company Limited; AstraZeneca; BGMA; Consilient Health Ltd; Daiichi sankyo Mexico. S.A de C.V.; Diamond PV Services; Elpen Pharmaceutical Co; European Commission; Glenmark Generics (Europe); Harrison Goddard Foote; IMS Health; Innovate Legal; Interpharm Consultancy; JADRAN Galenski laboratorij; Lebsa; London School Of Economics; LSE; Medicines Assessment Ltd ; Merck Serono International S.A.; MPA Business Services Ltd ; ntc pharma; Pharmawise; Research Centre for Pharmaceutical Care & Pharmaco-economics; Taylor Wessing; UQUIFA, S.A.;

Conference programme

8:30 Registration & Coffee

9:00 Chairman's Opening Remarks

Melanie Calvert

Melanie Calvert, Professor of Outcomes Methodology Primary Care Clinical Sciences, University Of Birmingham

9:10 Big data analytics…enabling the "insights from the whole patient populations to a sample"

Athula Herath

Athula Herath, Statistical Director, MedImmune

• On development of  a framework that may enable the analysis of  clinical data/standard care in real-time to keep abreast of latest clinical research related to drug development
• Introducing high-performance analytics to enable timely and accurate insights using
      o data mining
      o predictive analytics
      o modelling and simulation of the possible outcomes of a therapeutic intervention to stratify patient populations to sieve through the best interventions for a patient strata

9:50 Big data and the pharmaceutical industry: understanding how industry initiatives can move opportunities with big data forward for individual companies

Rob Thwaites

Rob Thwaites, Vice President, Health Economics and Epidemiology, Evidera, Chair, Pharmaceutical Industry Health Information Group, ABPI

• How has industry championed big data?...Examples from multiple countries
• Case study  - a decade of initiatives by industry in the UK
• Collaborative developments that will open up opportunities for companies in the future
• How can developments at an industry level help a company’s RWD strategy

10:30 Morning Coffee

11:00 Leveraging big data to study comparative effectiveness research (CER): a case example in multiple sclerosis

Niklas  Bergvall

Niklas Bergvall, Senior Director, Global HE&OR Neuroscience, Norvartis Pharmaceuticals

• Developing a systematic approach for identifying CER opportunities for pharma
• MS is a complex, chronic disease that requires monitoring of real-world effectiveness to inform clinical and economic decision-making.
• The use of data from multiple sources can overcome the limitations associated with assessing outcomes using a single source of information, such as individual database or registry studies.
• This combination of data sources provides useful critical information on real-world outcomes in a general MS population that can be used to complement data from clinical trials and observational studies in MS


11:40 Big data to individualize treatment; the cancer example

Hubert Caron

Hubert Caron, Professor Paediatric Oncology , Academic Medical Center University of Amsterdam

• Reviewing constitutional factors influencing reaction of the host on a drug
• Discussing cancer/host factors predicting clinical course, i.e. prognosis
• Tumour cell biology identifying validated tumor-driving genomic aberrations in drug-targeted genes/pathways ('predictive' biomarkers)

12:20 Networking Lunch

13:50 Leveraging existing data from legacy clinical trials

Pantaleo Nacci

Pantaleo Nacci , Head Statistical Reporting, Novartis Limited

• Discover a goldmine at your fingertips
• Understanding how to prepare it for use
• Choice of a (set of) standard(s)
• Evaluating future developments



14:30 Developing a robust and effective patient reported outcomes (PRO) strategy for clinical trials

Melanie Calvert

Melanie Calvert, Professor of Outcomes Methodology Primary Care Clinical Sciences, University Of Birmingham

• Understanding the essential elements required to create a successful PRO strategy
• Ensuring best practice for PRO use in trials, to improve the quality of PRO information collected for:
o clinical care
o decision-making
o predicting long-term outcomes
o informing health policy

15:10 Afternoon Tea

15:40 Beyond the horizon… building the ‘blueprint’ for a data-led pharmaceutical industry of the future

Rachel Uphill

Rachel Uphill, Enterprise / Information Architect, R&D IT Solutions, Delivery & Intgrtn, GlaxoSmithKline

• Understanding how the plethora of new data and improved analytical techniques can enhance future innovation and feed the drug-development pipeline
• Implementing standards, strategies and collaborations to enhance products and provide wider medical value
• Discovering what your peers are prioritizing as part of their own Big Dip strategies

16:20 Lessons learned so far! Understanding big data and its uses for the pharmaceutical world

• What has been learned 
• Evaluating what has and hasn’t worked
• What are the next steps in the big data strategy

Pantaleo Nacci

Pantaleo Nacci , Head Statistical Reporting, Novartis Limited

Athula Herath

Athula Herath, Statistical Director, MedImmune

17:00 Chairman’s Closing Remarks and Close of Day One

8:30 Registration & Coffee

9:00 Chairman's Opening Remarks

Athula Herath

Athula Herath, Statistical Director, MedImmune

9:10 Making more informed HEOR decisions with Big Data

Stephanie  Manson

Stephanie Manson, Director Value Evidence and Outcomes, GlaxoSmithKline

• Understanding the various applications for HEOR data in pharmaceuticals – an introduction to the value of HEOR
• Reviewing examples of how HEOR data has proved important and how this might be impacted by the use of big data
• Big data sources of real world observational data
• Embedding real-world data collection into clinical development programmes

9:50 Sensing life kinetics: rethinking clinical development

Judith  Kornfeld

Judith Kornfeld, Chief Business and Operations Officer , ORCATECH, Oregon Health & Science University

• Unobtrusive remote data collection provides valuable objective and relevant clinical information
• Continuous daily data capturing overcomes sporadic clinical measurements and is able to detect early treatment response signals rapidly
• Real life function and QoL measures can significantly increase efficacy of clinical development

10:30 Morning Coffee

11:00 Data opportunities from new pack coding rules (“serialisation”)

Mark Davison

Mark Davison, CEO, Blue Sphere Health Ltd

• Get a brief summary of coding initiatives in USA, EU, China etc              
• Hear how codes generate commercial potential (case study)
• Learn how patient engagement data will change pharma

11:40 Solving the hardest problem in pre-clinical data with a translation data platform

Justin Morley

Justin Morley, Solution Engineer, R&D Information Unit, AstraZeneca

• Reducing cycle times by rapid turnaround of modelling results on high quality and consistent in vivo data
• Don’t for forget the people: giving as much reward to the data generators as the data consumers to embed the transformation
• Signing up to the in vivo data contract to harness the power of complex data

12:20 Networking Lunch

13:50 A statistician's view on big data and data science

Diego Kuonen

Diego Kuonen, Chief Executive Officer, Statoo Consulting

• Demystifying the “big data” hype
• Demystifying the “data science” hype
• What distinguishes data science from statistics?
• Outlook, challenges and opportunities (not only for statisticians)

14:30 Love thy neighbour - creating stakeholder partnerships to maximize expertise capabilities and develop innovative medicines

• Understanding how collaboration can enhance drug research, development, commercialization and delivery
• Evaluating  how collaborative “open space” initiatives can enable specific questions or share insights to be addressed
• Learn how partnerships can harnessing Big Data for the development of innovative medicines
• Lessons learned from successful pharmaceutical, academic and CRO collaborations
• Building strategic relationships to maximize quality improvements,  economic value and cost effective outcomes

Stephanie  Manson

Stephanie Manson, Director Value Evidence and Outcomes, GlaxoSmithKline

Hisham  Mehanna

Hisham Mehanna, Chair of Head and Neck Surgery, School of Cancer Sciences. Director, Institute of Head and Neck Studies and Education, , University Of Birmingham

15:10 Afternoon Tea

15:40 Power of visualization: big data reporting and insights

Christopher Keenan

Christopher Keenan, Director, Governance & Operations, Global Medical Information , Bristol Myers Squibb

•         Exploring how to design and implement a global reporting framework encompassing all markets and languages
•         Understanding how to build a consensus
•         Realizing the importance of data governance and stewardship
•         Converting data into actionable objectives
•         Power of Visualization

16:20 Improving pharmaceutical marketing performance using big data solutions

Paul Grant

Paul Grant, CIO, Creation Healthcare

• Developing a digital marketing strategy in the data age • Optimising customer insights using machine learning and natural language processing • Leveraging social and behavioural analytics to understand customer perception of brand messaging and intent • Integrating data sources for enhanced ‘Social CRM’ • Appropriate customer engagement at the right time, in the right place, with the right content

17:00 Chairman’s Closing Remarks and Close of Day Two



Holiday Inn Regents Park

Carburton Street
London W1W 5EE
United Kingdom

Holiday Inn Regents Park

Choose the well-connected Holiday Inn London-Regent's Park hotel, with a superb central London location and speedy transport links. Holiday Inn London-Regent's Park is in a leafy and cosmopolitan area of central London, a 10-minute walk from bustling Oxford Street. Leave your car in our NCP managed underground car park, and explore London by Tube. Great Portland Street Tube station is 25 metres from the hotel, from where you can reach the City and Canary Wharf in 30 minutes, and London Heathrow Airport in 45 minutes.

Wireless Internet is available throughout the hotel, and you can invite up to 300 people to events at the Academy Conference Centre, with an IT technician and break-out zones. Holiday Inn London-Regent's Park is a 10-minute walk from Santander's offices and businesses in the BT Tower. Stroll 5 minutes to Regent's Park, where you'll find London Zoo and pretty Primrose Hill. We're a 10-minute walk from Bond Street boutiques and 20 minutes from Buckingham Palace and cruises on the River Thames.

Ask our Concierge to plan your day out and book West End theatre tickets. Room Service is available 24 hours at Holiday Inn London-Regent's Park, or dine in the vibrant Junction Restaurant. Our Junction Bar has a menu of light bites, and a hot breakfast buffet is served daily.



speaker image






CPD stands for Continuing Professional Development’. It is essentially a philosophy, which maintains that in order to be effective, learning should be organised and structured. The most common definition is:

‘A commitment to structured skills and knowledge enhancement for Personal or Professional competence’

CPD is a common requirement of individual membership with professional bodies and Institutes. Increasingly, employers also expect their staff to undertake regular CPD activities.

Undertaken over a period of time, CPD ensures that educational qualifications do not become obsolete, and allows for best practice and professional standards to be upheld.

CPD can be undertaken through a variety of learning activities including instructor led training courses, seminars and conferences, e:learning modules or structured reading.


There are approximately 470 institutes in the UK across all industry sectors, with a collective membership of circa 4 million professionals, and they all expect their members to undertake CPD.

For some institutes undertaking CPD is mandatory e.g. accountancy and law, and linked to a licence to practice, for others it’s obligatory. By ensuring that their members undertake CPD, the professional bodies seek to ensure that professional standards, legislative awareness and ethical practices are maintained.

CPD Schemes often run over the period of a year and the institutes generally provide online tools for their members to record and reflect on their CPD activities.


Professional bodies and Institutes CPD schemes are either structured as ‘Input’ or ‘Output’ based.

‘Input’ based schemes list a precise number of CPD hours that individuals must achieve within a given time period. These schemes can also use different ‘currencies’ such as points, merits, units or credits, where an individual must accumulate the number required. These currencies are usually based on time i.e. 1 CPD point = 1 hour of learning.

‘Output’ based schemes are learner centred. They require individuals to set learning goals that align to professional competencies, or personal development objectives. These schemes also list different ways to achieve the learning goals e.g. training courses, seminars or e:learning, which enables an individual to complete their CPD through their preferred mode of learning.

The majority of Input and Output based schemes actively encourage individuals to seek appropriate CPD activities independently.

As a formal provider of CPD certified activities, SMI Group can provide an indication of the learning benefit gained and the typical completion. However, it is ultimately the responsibility of the delegate to evaluate their learning, and record it correctly in line with their professional body’s or employers requirements.


Increasingly, international and emerging markets are ‘professionalising’ their workforces and looking to the UK to benchmark educational standards. The undertaking of CPD is now increasingly expected of any individual employed within today’s global marketplace.

CPD Certificates

We can provide a certificate for all our accredited events. To request a CPD certificate for a conference , workshop, master classes you have attended please email events@smi-online.co.uk

Event Title


Read More

I would like to speak at an event

I would like to attend an event

I would like to sponsor/exhibit at an event


Sign up
Forgotten Password?


UK Office
Opening Hours: 9.00 - 17.30 (local time)
SMi Group Ltd, 1 Westminster Bridge Road, London, SE1 7XW, United Kingdom
Tel: +44 (0) 20 7827 6000 Fax: +44 (0) 20 7827 6001
Website: http://www.smi-online.co.uk Email: events@smi-online.co.uk
Registered in England No: 3779287 VAT No: GB 976 2951 71

Forgotten Password

Please enter the email address you registered with. We will email you a new password.

Thank you for visiting our event

If you would like to receive further information about our events, please fill out the information below.

By ticking above you are consenting to receive information by email from SMi.
Full details of our privacy policy can be found here https://www.smi-online.co.uk/privacy-legals/privacy-policy/.
Should you wish to update your contact preferences at any time you can contact us at data@smi-online.co.uk.
Should you wish to be removed from any future mailing lists please click on the following link http://www.smi-online.co.uk/opt-out